191 related articles for article (PubMed ID: 15010644)
1. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study.
Barzilay JI; Davis BR; Bettencourt J; Margolis KL; Goff DC; Black H; Habib G; Ellsworth A; Force RW; Wiegmann T; Ciocon JO; Basile JN;
J Clin Hypertens (Greenwich); 2004 Mar; 6(3):116-25. PubMed ID: 15010644
[TBL] [Abstract][Full Text] [Related]
2. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
[TBL] [Abstract][Full Text] [Related]
3. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group
Hypertension; 2003 Sep; 42(3):239-46. PubMed ID: 12925554
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
[TBL] [Abstract][Full Text] [Related]
5. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.
Davis BR; Cutler JA; Furberg CD; Wright JT; Farber MA; Felicetta JV; Stokes JD;
Ann Intern Med; 2002 Sep; 137(5 Part 1):313-20. PubMed ID: 12204014
[TBL] [Abstract][Full Text] [Related]
6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
7. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS;
Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826
[TBL] [Abstract][Full Text] [Related]
10. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
[TBL] [Abstract][Full Text] [Related]
11. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Davis BR; Kostis JB; Simpson LM; Black HR; Cushman WC; Einhorn PT; Farber MA; Ford CE; Levy D; Massie BM; Nawaz S;
Circulation; 2008 Nov; 118(22):2259-67. PubMed ID: 19001024
[TBL] [Abstract][Full Text] [Related]
12. Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Lasagna L
JAMA; 2000 Apr; 283(15):2013-4. PubMed ID: 10789671
[No Abstract] [Full Text] [Related]
13. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
JAMA; 2008 Jan; 299(3):296-307. PubMed ID: 18212314
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Reisin E; Graves JW; Yamal JM; Barzilay JI; Pressel SL; Einhorn PT; Dart RA; Retta TM; Saklayen MG; Davis BR;
J Hypertens; 2014 Jul; 32(7):1503-13; discussion 1513. PubMed ID: 24842697
[TBL] [Abstract][Full Text] [Related]
17. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Curb JD; Pressel SL; Cutler JA; Savage PJ; Applegate WB; Black H; Camel G; Davis BR; Frost PH; Gonzalez N; Guthrie G; Oberman A; Rutan GH; Stamler J
JAMA; 1996 Dec; 276(23):1886-92. PubMed ID: 8968014
[TBL] [Abstract][Full Text] [Related]
18. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
[TBL] [Abstract][Full Text] [Related]
19. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Pressel SL; Davis BR; Wright JT; Geraci TS; Kingry C; Ford CE; Piller LB; Bettencourt J; Kimmel B; Lusk C; Parks H; Simpson LM; Nwachuku C; Furberg CD;
Control Clin Trials; 2001 Feb; 22(1):29-41. PubMed ID: 11165421
[TBL] [Abstract][Full Text] [Related]
20. Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?
Grimm RH; Davis BR; Piller LB; Cutler JA; Margolis KL; Barzilay J; Dart RA; Graumlich JF; Murden RA; Randall OS;
J Clin Hypertens (Greenwich); 2009 Sep; 11(9):466-74. PubMed ID: 19751458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
